#1 Clinical Trials Search in Europe

Danazol

Danazol, a synthetic steroid hormone, has been the subject of several clinical trials investigating its potential therapeutic benefits for a range of medical conditions. These trials have explored the use of danazol in treating blood disorders, liver diseases, and other rare genetic conditions. This article summarizes the key findings from recent clinical trials using danazol, providing insights into its efficacy, safety, and potential applications in medical treatment.

Table of Contents

Introduction

Danazol is a synthetic hormone medication that has been used for several decades to treat various medical conditions. This article aims to provide patients with a comprehensive understanding of Danazol, its uses, benefits, and potential side effects based on recent clinical trials and research.[1][2][3][4][5]

What is Danazol?

Danazol is a synthetic steroid hormone that structurally resembles natural androgens (male hormones) found in the body. It is known by several other names, including Danocrine, Danol, and Danatrol.[2] Danazol has been approved by the Food and Drug Administration (FDA) for treating certain medical conditions, but it is also being studied for its potential benefits in other disorders.

Medical Conditions Treated with Danazol

Danazol is used to treat or being investigated for the following conditions:

  • Telomere-related disorders: These are genetic conditions affecting the ends of chromosomes, which can lead to bone marrow failure and lung problems.[1][4]
  • Fanconi anemia and Dyskeratosis congenita: Inherited bone marrow failure syndromes.[2]
  • Thrombotic Thrombocytopenic Purpura (TTP): A rare blood disorder causing blood clots to form in small blood vessels throughout the body.[3]
  • Aplastic anemia: A condition where the bone marrow doesn’t produce enough new blood cells.[4]
  • Immune Thrombocytopenia (ITP): A disorder that can lead to easy or excessive bruising and bleeding due to low levels of platelets.[5]

How Danazol Works

Danazol’s mechanism of action varies depending on the condition being treated:

  • For telomere-related disorders: Danazol may help increase telomerase activity, potentially slowing down or reversing telomere shortening.[1][4]
  • In bone marrow failure syndromes: It may stimulate blood cell production and have immune-modifying effects.[2]
  • For TTP: Danazol may work in conjunction with plasma exchange to reduce the number of treatments needed.[3]
  • In ITP: It may help increase platelet counts when used alone or in combination with other medications.[5]

Dosage and Administration

The dosage of Danazol varies depending on the condition being treated and the patient’s response. Some common dosage regimens from the clinical trials include:

  • For telomere-related disorders: 800 mg daily, taken orally in divided doses for up to 24 months.[1][4]
  • For Fanconi anemia and Dyskeratosis congenita: Starting at 5 mg/kg/day, potentially increasing to 15 mg/kg/day (not exceeding 800 mg/day) based on response.[2]
  • For TTP: 600 mg daily, taken orally.[3]
  • For ITP: 200 mg twice daily for 12 weeks.[5]

It’s important to note that dosages should always be determined by a healthcare professional based on individual patient needs and responses.

Potential Side Effects

While Danazol can be effective in treating various conditions, it may cause side effects. Some potential side effects observed in clinical trials include:

  • Virilization (development of male characteristics in females)
  • Liver function abnormalities
  • Changes in cholesterol levels
  • Prostate-specific antigen (PSA) level changes in men
  • Weight gain
  • Acne
  • Changes in menstrual cycles for women

It’s crucial to discuss potential side effects with your healthcare provider and report any unusual symptoms during treatment.[1][2][4]

Ongoing Research and Clinical Trials

Several clinical trials are currently investigating the efficacy and safety of Danazol for various conditions:

  • A study evaluating Danazol’s effect on telomere length in patients with telomere-related disorders.[1]
  • Research on Danazol’s potential to reduce the number of plasma exchanges needed in TTP treatment.[3]
  • A trial comparing the combination of Sitagliptin and Danazol versus Danazol alone for treating steroid-resistant or relapsed ITP.[5]

These ongoing studies aim to provide more information about Danazol’s effectiveness, optimal dosing, and long-term safety in various conditions.

Frequently Asked Questions

1. How long does it take for Danazol to work?

The time it takes for Danazol to show effects can vary depending on the condition being treated. In some studies, patients were evaluated for response after 12-24 weeks of treatment. However, individual responses may vary, and your doctor will monitor your progress closely.

2. Can Danazol be used in children?

Some clinical trials have included patients as young as 2 years old for certain conditions. However, the use of Danazol in children should be carefully considered and monitored by a healthcare professional due to potential effects on growth and development.

3. Are there any alternatives to Danazol?

Depending on the condition being treated, there may be alternative treatments available. For example, in bone marrow failure syndromes, other options might include different androgens, immunosuppressive therapy, or stem cell transplantation. It’s important to discuss all treatment options with your healthcare provider to determine the best approach for your specific situation.

Summary Table

Aspect Details
Drug Name Danazol (also known as Danocrine, Danol, Danatrol)
Drug Type Synthetic steroid hormone (androgen)
Main Uses Telomere-related disorders, bone marrow failure syndromes, TTP, ITP
Common Dosage Range 200-800 mg daily, depending on condition
Administration Oral capsules
Treatment Duration Varies; can be from 12 weeks to 24 months or longer
Main Side Effects Virilization, liver function changes, cholesterol level changes

Glossary

  • Telomere – The end part of a chromosome that protects it from deterioration
  • Androgen – A type of hormone that stimulates or controls the development and maintenance of male characteristics
  • Thrombotic Thrombocytopenic Purpura (TTP) – A rare blood disorder characterized by blood clots forming in small blood vessels throughout the body
  • Immune Thrombocytopenia (ITP) – A blood disorder characterized by a decrease in the number of platelets in the blood
  • Virilization – The development of male physical characteristics, typically in a female
  • Telomerase – An enzyme that helps maintain the length of telomeres

Trial Sources

  • [1]: https://clinicaltrials.gov/study/NCT03710356
  • [2]: https://clinicaltrials.gov/study/NCT01001598
  • [3]: https://clinicaltrials.gov/study/NCT00953771
  • [4]: https://clinicaltrials.gov/study/NCT01441037
  • [5]: https://clinicaltrials.gov/study/NCT05353673
Condition Study Design Dosage Key Findings
Fanconi anemia and Dyskeratosis congenita Phase I/II dose escalation trial 5-15 mg/kg/day for 24 weeks Investigated safety and efficacy, focusing on hematologic response and genetic expression profiles
Thrombotic Thrombocytopenic Purpura (TTP) Phase II study 600 mg daily with plasma exchange and corticosteroids Aimed to reduce the number of plasma exchanges required to control TTP
Telomere-related diseases Phase II trial 800 mg daily for 2 years Showed potential in attenuating telomere attrition and improving blood counts
Immune Thrombocytopenia (ITP) Randomized controlled trials 200 mg twice daily, often in combination with other drugs Investigated efficacy in combination with drugs like sitagliptin, tacrolimus, and teriflunomide
Cytopenias in Cirrhosis Phase II pilot study 600 mg daily for 24 months Assessed safety and efficacy in improving blood cell counts in cirrhosis patients

FAQ

  • What conditions is danazol being studied for in clinical trials? Danazol is being studied for various conditions including Fanconi anemia, dyskeratosis congenita, thrombotic thrombocytopenic purpura, immune thrombocytopenia, telomere-related diseases, and cytopenias in patients with cirrhosis.
  • How does danazol work in the body? Danazol is a synthetic steroid hormone that suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. It has immune-modifying activity and can affect telomere length in some conditions.
  • What are some potential benefits of danazol treatment? Potential benefits of danazol include improving blood cell counts, reducing the need for blood transfusions, slowing telomere attrition, and potentially improving liver and lung function in certain conditions.
  • What are common side effects of danazol? Common side effects of danazol include androgen-like effects such as weight gain, acne, mild hirsutism, edema, hair loss, and voice changes. It can also cause menstrual disturbances and elevations in liver enzyme levels.
  • Is danazol being studied in combination with other drugs? Yes, some clinical trials are investigating the combination of danazol with other drugs such as sitagliptin, tacrolimus, teriflunomide, and terbutaline for conditions like immune thrombocytopenia.

Ongoing Clinical Trials on Danazol

  • Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Hungary +3

  • Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia France Germany Greece +7

  • Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +4

  • Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Hungary Italy Romania Spain

  • Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Czechia France Hungary Italy Poland +2

Glossary

  • Telomeres: Repetitive DNA sequences located at the ends of chromosomes that protect them from damage and degradation.
  • Fanconi anemia: A rare inherited blood disorder that leads to bone marrow failure and increased risk of certain cancers.
  • Dyskeratosis congenita: A rare genetic disorder characterized by skin abnormalities, nail dystrophy, and bone marrow failure.
  • Thrombotic thrombocytopenic purpura (TTP): A rare blood disorder characterized by blood clots in small blood vessels throughout the body.
  • Immune thrombocytopenia (ITP): A blood disorder characterized by a decreased number of platelets in the blood due to immune system dysfunction.
  • Cytopenia: A condition in which there is a lower-than-normal number of blood cells in the body.
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions.
  • Telomerase: An enzyme that helps maintain telomere length by adding DNA sequence repeats to the ends of chromosomes.
  • Hematologic response: An improvement in blood cell counts or other blood-related parameters in response to treatment.
  • Androgen: A group of hormones that play a role in male traits and reproductive activity.